论文部分内容阅读
目的观察孟鲁司特治疗儿童咳嗽变异性哮喘(CVA)的疗效。方法 65例CVA患儿随机分成治疗组32例和对照组33例,对照组给予口服盐酸丙卡特罗(美普清)和酮替芬;治疗组在对照组的基础上加用孟鲁司特咀嚼片,总疗程3个月。观察两组疗效,随访6个月,追踪复发情况。结果治疗组达到临床缓解所需时间及随访半年的复发率均明显低于对照组(P<0.01和P<0.05),且未见明显不良反应。结论孟鲁司特治疗儿童咳嗽变异性哮喘疗效确切,不良反应少,复发率低,值得临床推广。
Objective To observe the efficacy of montelukast in the treatment of children with cough variant asthma (CVA). Methods Sixty-five children with CVA were randomly divided into treatment group (32 cases) and control group (33 cases). The control group was given oral procaterol hydrochloride and ketotifen. The treatment group was treated with montelukast Chewable tablets, the total course of 3 months. The curative effect of two groups were observed and followed up for 6 months to track the recurrence. Results The treatment group achieved the clinical remission time and the recurrence rate of six months follow-up were significantly lower than the control group (P <0.01 and P <0.05), and no significant adverse reactions. Conclusion Montelukast treatment of children with cough variant asthma is effective, less adverse reactions, low recurrence rate, worthy of clinical promotion.